Log In
Print
BCIQ
Print
Print this Print this
 

blisibimod (A-623) (formerly AMG 623)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionPeptide fusion protein that antagonizes BLyS (BAFF)
Molecular Target BLyS (BAFF)
Mechanism of ActionBLyS (BAFF) receptor antagonist
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today